Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE8B | O95263 | 1/20 | 0.46 |
| ▸ | ATM | Q13315 | 2/20 | 0.46 |
| ▸ | CHEK2 | O96017 | 1/20 | 0.44 |
| ▸ | KDM1A | O60341 | 1/20 | 0.41 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.40 |
| ▸ | HPGD | P15428 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3146378 | 0.87 | ATM (0.47) | PDE8BATMCHEK2KDM1AHSD17B10 | |
| SCHEMBL25218855 | 0.87 | ATM (0.47) | PDE8BATMCHEK2KDM1AHSD17B10 | |
| SCHEMBL25220677 | 0.87 | ATM (0.47) | PDE8BATMCHEK2KDM1AHSD17B10 | |
| SCHEMBL7983676 | 0.86 | ATM (0.47) | PDE8BATMCHEK2KDM1AHSD17B10 | |
| SCHEMBL31037649 | 0.86 | PDE8B (0.47) | PDE8BATMCHEK2KDM1AHSD17B10 | |
| SCHEMBL23015233 | 0.86 | PDE8B (0.47) | PDE8BATMCHEK2KDM1AHSD17B10 | |
| SCHEMBL31436239 | 0.86 | PDE8B (0.47) | PDE8BATMCHEK2KDM1AHSD17B10 | |
| SCHEMBL1009587 | 0.86 | PDE8B (0.47) | PDE8BATMCHEK2KDM1AHSD17B10 | |
| SCHEMBL16083940 | 0.85 | PDE8B (0.46) | PDE8BATMCHEK2KDM1AHSD17B10 | |
| SCHEMBL6157710 | 0.85 | ATM (0.47) | PDE8BATMCHEK2KDM1AHSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9771372-B2 | Compounds useful as S100-inhibitors | ACTIVE BIOTECH AB (SE) | 2017-09-26 | — | — | US | disclosed |
| US-20170204098-A1 | NOVEL COMPOUNDS USEFUL AS S100-INHIBITORS | ACTIVE BIOTECH AB (SE) | 2017-07-20 | — | — | US | disclosed |
| EP-2991990-B1 | NOVEL COMPOUNDS USEFUL AS S100-INHIBITORS | ACTIVE BIOTECH AB (SE) | 2017-02-01 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170204098-A1 | NOVEL COMPOUNDS USEFUL AS S100-INHIBITORS | S100A9, S100A4, S100B | PDE8B 4458/4885ATM 2855/4885CHEK2 2794/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.